Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients

Table 6

Description of patients and adverse events displayed during the study.

Variable	Total n = 103 (%)
No. of subjects who presented AE	20 (19.4)
Age, years (mean, SD)	60.1 ± 13.9
Gender (men, %)	10 (50.0)
Adverse event	24 (%)
COVID-19 pneumonia	2 (8.3)
COVID-19	3 (12.5)
Viral bronchitis	1 (4.2)
Increased liver enzyme	3 (12.5)
Atrial fibrillation	1 (4.2)
Diabetic nephropathy	1 (4.2)
Constipation	1 (4.2)
Herpes zoster	1 (4.2)
Depression	2 (8.3)
Increased amylase	1 (4.2)
Irritable bowel syndrome	1 (4.2)
Cervicitis	1 (4.2)
Dizziness	1 (4.2)
Hyperkalemia	1 (4.2)
Pharyngitis	1 (4.2)
Orthostatic hypotension	1 (4.2)
Myalgia	1 (4.2)
Urinary tract infection by E. coli	1 (4.2)
Seriousness
Serious	2 (8.3)
Nonserious	22 (91.7)
Severity
Mild	9 (37.5)
Moderate	15 (62.5)
Causality
Improbable	13 (54.2)
Possible	10 (41.7)
Probable	1 (4.2)
Expectability
Expected	7 (29.2)
Unexpected	17 (70.8)

Reported with frequencies (percentages). Although a hyperkalemia adverse event was reported, the median potassium concentrations were not above the normal range at any time during the follow up of patients.